Abstract
Literature to date has strongly suggested that linoleic acid (LA) enhances mammary cancer cell proliferation when used in the range of 0·5–20 μg/ml. In contrast, the current in vitro studies show that deoxyribonucleic acid (DNA) levels of estrogen receptor-positive (ER+) MCF7 breast cancer cells were diminished following treatment with 30 μg/ml (100 μM) LA. MCF7 cells, when treated for 6 days with LA, consumed significantly less glucose than untreated controls (P-value<0·01). MFC7 cells treated with 30 μg/ml LA and 10 μM tamoxifen had even lower levels of DNA and lower glucose uptake. The same combination treatment of tamoxifen and LA was applied to a noncancerous mammary cell line, MCF10A, and did not have a significant effect on MCF10A DNA concentrations. Linoleic acid and its byproducts are important to cell proliferation and tissue reconstruction and, in combination with tamoxifen, can provide a uniquely different approach to soft tissue engineering. That is, LA and tamoxifen-loaded scaffolds may provide a viable reconstructive approach for patients undergoing lumpectomy and mastectomy by encouraging natural breast healing while limiting the ability of ER+ cancer cells to regrow. This approach could allow the suppression of estrogen-dependent mammary carcinomas while allowing natural cell proliferation after a mastectomy or lumpectomy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
